Corneal topography

Heidelberg Engineering Showcases the Future of Imaging, Extending Its Capabilities With a Breadth of Research Technology

Retrieved on: 
Tuesday, April 30, 2024
Technology, Biotechnology, Health, Apps, Applications, Surgery, Optical, Artificial Intelligence, Research, Medical Devices, General Health, Health Technology, Science, Data Management, Clinical Trials, FDA, University, IOL, DICOM, AI, Bausch & Lomb, Biostatistics, Artificial intelligence, 3D, SRT, OCT, Algorithm, Epithelium, Corneal topography, Google Images, ARVO, ETM, Tomography, Medical imaging

For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.

Key Points: 
  • For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.
  • The groundbreaking, fully digital, surgical-visualization platform features next-generation image technology with state-of-the-art intraoperative OCT that will transform the modern OR.
  • "In 2025, Heidelberg Engineering is set to revolutionize basic vision science with the introduction of the Heidelberg CHAMELEON Imaging Research Platform," said Heidelberg Engineering Clinical Development Manager — Investigational Technologies, Dr. Sebastian Rausch.
  • Monday night, Heidelberg Engineering will host an award presentation for the winner of the Heidelberg Engineering Xtreme Research Award that recognizes aspiring researchers for their outstanding contribution to ophthalmic research.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024
FDA, General Health, Optical, Health, IOP, Telecanthus, Patient, Ophthalmology, Failure, Corneal topography, Food, Autoimmune disease, Contraindication, Risk, Floater, Sale, Near-sightedness, CTK, Pain, Retinal detachment, User, Bleeding, Surgeon, Diabetes, Dry, Eye, Side, Dry eye syndrome, Posture, Laser, Visual acuity, Neuropathic pain, Engineering, Infection, Use, Keratoconus, Safety, Magnetic resonance, Bausch & Lomb, Glaucoma, Hospital

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

20/20NOW and Visionix Announce Strategic Alliance

Retrieved on: 
Friday, November 10, 2023
Corneal topography, Patient, Marketing, Health care

HOLBROOK, N.Y., Nov. 10, 2023 /PRNewswire/ -- 20/20NOW, 20/20NOW and Visionix USA have announced a strategic alliance to bring Tele-Optometry to more eye care professionals and optical retailers in North America.

Key Points: 
  • HOLBROOK, N.Y., Nov. 10, 2023 /PRNewswire/ -- 20/20NOW, 20/20NOW and Visionix USA have announced a strategic alliance to bring Tele-Optometry to more eye care professionals and optical retailers in North America.
  • According to Robert Iasillo, VP of Sales and Marketing at 20/20NOW, "Visionix offers state-of-the-art diagnostic ophthalmic devices that integrate with 20/20NOW's Tele-Optometry Platform and Professional Services.
  • One example of this strategic alliance is, 20/20NOW will be utilizing the new VX650 multi-testing platform from Visionix that performs automated pretesting in one device, including auto-refraction, non-contact tonometry, corneal topography, pachymetry as well as anterior and poster segment imaging.
  • This strategic alliance will enable us to preserve the standard of care through meaningful innovation and delivering quality comprehensive eye exams in under 20 minutes from start to finish."

Heidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Retrieved on: 
Friday, October 13, 2023
Apps, Applications, Technology, Medical Devices, FDA, Health Technology, Software, Biotechnology, Hardware, Health, Optical, Diagnosis, Multimedia, Lumia imaging apps, Acquisition, Corneal topography, Aqueous humour, OD, OCT, Clinical trial, Cataract, Heidelberg, IOL, Tomography, Cornea, Medical device, Medical imaging, Telescopic sight

Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.

Key Points: 
  • Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.
  • View the full release here: https://www.businesswire.com/news/home/20231013216160/en/
    “Building upon our previous CE-marking, we are thrilled that the ANTERION platform is now available to eye care providers across the U.S.,” said Arianna Schoess Vargas, Managing Director of Heidelberg Engineering GmbH.
  • Central to the ANTERION platform is the Imaging App, which was FDA cleared in November 2021.
  • For more information about ANTERION, visit our website or contact us directly.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023
Visio, Specialist, Presbyopia, Telecanthus, Patient, LASIK, Adjoint, Near-sightedness, ATLAS, ELANA, University, Corneal topography, University of Colorado, Cataract, Aqueous humour, LVC, Retina, Far-sightedness, Refractive surgery, AT, SLT, Eye, Iridectomy, Glaucoma, Surgeon, FEBO, Quality of life, SMILE, Pupillometry, Assistant professor, Astigmatism, European Society for Medical Oncology, Robotics, Visual acuity, Charles University, Telescopic sight, Medical imaging, Medical device, Ophthalmology, ZEISS, IOL

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023
Visio, Specialist, Presbyopia, Telecanthus, Patient, LASIK, Adjoint, Near-sightedness, ATLAS, ELANA, University, Corneal topography, University of Colorado, Cataract, Aqueous humour, LVC, Retina, Far-sightedness, Refractive surgery, AT, SLT, Eye, Iridectomy, Glaucoma, Surgeon, FEBO, Quality of life, SMILE, Pupillometry, Assistant professor, Astigmatism, European Society for Medical Oncology, Robotics, Visual acuity, Charles University, Telescopic sight, Medical imaging, Medical device, Ophthalmology, ZEISS, IOL

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

Retrieved on: 
Monday, June 5, 2023
Health, Health Technology, Clinical Trials, Pharmaceutical, Optical, Biotechnology, GKOS, Glaucoma, Food, NDA, Corneal topography, Retina, Keratoconus, Corporation, Patient, EPI, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Safety, Pharmaceutical industry, 1870 Glaukos

“We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.

Key Points: 
  • “We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.
  • The study eyes were randomized in a 2:1 ratio to receive Epioxa therapy or placebo and sham procedure control treatment.
  • Results from this second Phase 3 confirmatory pivotal trial together with the already-completed first Phase 3 pivotal trial are expected to support Glaukos’ targeted NDA submission for Epioxa by the end of 2024.
  • As a reminder, the U.S. FDA has confirmed Glaukos’ first Phase 3 pivotal trial for Epioxa, which met the pre-specified primary efficacy endpoint, would be adequate to support the submission and review of an eventual NDA, in conjunction with this second Phase 3 trial.

ZEISS Presents New Surgical Workflow Innovations at ASCRS

Retrieved on: 
Tuesday, May 2, 2023
Cornea, CT, Surgeon, Refractive surgery, ATLAS, Cataract, Quality of life, Corneal topography, Gyration tensor, ASCRS, Pathology, Doctor of Philosophy, American Society of Cataract and Refractive Surgery, U.S. FDA, Gaussian beam, Intraocular lens, Capsulotomy, Patient, Ophthalmology, Architecture, ZEISS, Diagnosis, Health, Conference, FDA, Society, ZO, LVC, Dentistry, Medical device, Medical imaging, Telescopic sight, IOL

JENA, Germany and DUBLIN, Calif., May 2, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new surgical workflow innovations at the American Society of Cataract and Refractive Surgery (ASCRS) annual conference from May 6-8, 2023, in San Diego, CA. These products as part of the ZEISS Medical Ecosystem help enhance ophthalmic care within the cataract and corneal refractive workflows for improved diagnosis and treatment efficiency of surgical patients:

Key Points: 
  • JENA, Germany and DUBLIN, Calif., May 2, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new surgical workflow innovations at the American Society of Cataract and Refractive Surgery (ASCRS) annual conference from May 6-8, 2023, in San Diego, CA.
  • These products as part of the ZEISS Medical Ecosystem help enhance ophthalmic care within the cataract and corneal refractive workflows for improved diagnosis and treatment efficiency of surgical patients:
    The ATLAS™ 500 from ZEISS supports more efficient surgical diagnostics enhancing patient outcomes.
  • The CT LUCIA® 621P Monofocal IOL from ZEISS received U.S. FDA approval, offering a unique ZEISS Optic to treat a wide range of cataract patients.
  • ZEISS will showcase its new surgical workflow solutions during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Conference from May 6-8, 2023, at booth 1437.

Global Corneal Topographers Market Report 2021: Market to Reach $834.3 Million by 2027 - Placido Disc System to Account for $350 Million - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Other Manufacturing, Manufacturing, Actuarial science, Compound annual growth rate, Mathematical finance, Corneal topography, Articles

The "Corneal Topographers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Corneal Topographers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Corneal Topographers estimated at US$607.6 Million in the year 2020, is projected to reach a revised size of US$834.3 Million by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027.
  • Placido Disc System, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$350 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $164 Million, While China is Forecast to Grow at 7.4% CAGR
    The Corneal Topographers market in the U.S. is estimated at US$164 Million in the year 2020.